Amgen Forecast, price target & analysts
$465.67
0.30%
NYSE, Nov 13, 04:04 pm EST.
Closed.
Index
Industry
Amgen Target price 2026 - Analyst rating & recommendation
Powered by
Amgen Classifications & Recommendation
Buy
43%
Hold
48%
Sell
10%
Amgen Price Target
| Target Price | $418.20 |
| Price | $465.67 |
| Deviation | 10.19% |
| Number of Estimates | 34 |
| 34 Analysts have issued a price target Amgen 2027 . The average Amgen target price is $418.20. This is 10.19% lower than the current stock price. The highest price target is $525.00 12.74% , the lowest is $227.25 51.20% . | |
| A rating was issued by 42 analysts: 18 Analysts recommend Amgen to buy, 20 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2027 of 10.19% . Most analysts recommend the Amgen stock at Hold. |
Sales and Margin forecast 2026, 2027 to 2033
Sign up for free to unlock analyst estimates.
Sign up for free
Powered by
36 Analysts have issued a sales forecast Amgen 2026 . The average Amgen sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
37 Amgen Analysts have issued a net profit forecast 2026. The average Amgen net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
Sign up for free to unlock analyst estimates.
Sign up for free
Powered by
Current Amgen Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Freedom Broker |
Buy
➜
Hold
|
Downgrade | Nov 06 2026 |
| Guggenheim |
Neutral
➜
Neutral
|
Unchanged | Nov 05 2026 |
| Leerink Partners |
Market Perform
➜
Market Perform
|
Unchanged | Nov 05 2026 |
| Canaccord Genuity |
Hold
➜
Hold
|
Unchanged | Nov 04 2026 |
| Cantor Fitzgerald |
Neutral
➜
Neutral
|
Unchanged | Nov 04 2026 |
| Citigroup |
Neutral
➜
Neutral
|
Unchanged | Nov 04 2026 |
| Bernstein |
Market Perform
➜
Market Perform
|
Unchanged | Nov 04 2026 |
| Analyst Rating | Date |
|---|---|
|
Downgrade
Freedom Broker:
Buy
➜
Hold
|
Nov 06 2026 |
|
Unchanged
Guggenheim:
Neutral
➜
Neutral
|
Nov 05 2026 |
|
Unchanged
Leerink Partners:
Market Perform
➜
Market Perform
|
Nov 05 2026 |
|
Unchanged
Canaccord Genuity:
Hold
➜
Hold
|
Nov 04 2026 |
|
Unchanged
Cantor Fitzgerald:
Neutral
➜
Neutral
|
Nov 04 2026 |
|
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Nov 04 2026 |
|
Unchanged
Bernstein:
Market Perform
➜
Market Perform
|
Nov 04 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
